ライフサイエンスコーパス: glycate

1 by all three primary assays and in all four glycated 2D subfractions were significantly different be

2 At pH 7 glycated actomyosin was on average 31% more soluble comp

3 es the metabolism of reactive metabolite and glycating agent methylglyoxal-may improve metabolic and

4 Methylglyoxal (MG), an arginine-directed glycating agent, is implicated in diabetic late complica

5 CKD by fructosamine (C statistic 0.717) and glycated albumin (0.717) were nearly as strong as by HbA

6 eins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in the blood, are essential indica

7 its daily variability, we compared HbA(1c), glycated albumin (GA), and seven-point glucose profile c

8 an HbA1c in meta-analysis (P = 0.0225), mean glycated albumin (P = 0.0029), and glyoxal hydroimidazol

9 HRs for CKD for people with fructosamine and glycated albumin above the 95th percentile were 1.50 (95

10 the 95th percentile and 6.17 (5.45-6.99) for glycated albumin above the 95th percentile.

11 We measured glycated albumin and fructosamine in 11 104 participants

12 We measured glycated albumin and fructosamine in blood samples from

13 ifferences were found in the relationship of glycated albumin and fructosamine levels with the mean g

14 The extent of glycation measured in terms of glycated albumin and hemoglobin was reduced significantl

15 Fructosamine and glycated albumin are markers of short-term (2-4 weeks) g

16 Fructosamine and glycated albumin are markers of short-term glycemic cont

17 people with no diabetes and fructosamine or glycated albumin below the 75th percentile.

18 26), but HbA1c outperformed fructosamine and glycated albumin for prediction of incident diabetes wit

19 clarify the performance of fructosamine and glycated albumin measurements for identifying people at

20 We found that fructosamine and glycated albumin were associated with vascular outcomes

21 baseline concentrations of fructosamine and glycated albumin were significantly associated with each

22 Fructosamine and glycated albumin were strongly associated with incident

23 Fructosamine and glycated albumin were strongly associated with retinopat

24 e evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, is

25 ssessed the associations of fructosamine and glycated albumin with risk of incident diabetes, retinop

26 , glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable for kidney func

27 monitoring and compared by race with HbA1c, glycated albumin, and fructosamine values.

28 d fasting glucose, insulin, adiponectin, and glycated albumin, as well as body mass index (BMI), use

29 The percentage of glycated alpha-Hb and beta-Hb was calculated from the mi

30 case that repairs methylglyoxal- and glyoxal-glycated amino acids and proteins by acting on early gly

31 nes, arginines, and lysines (the three major glycated amino acids) of serum albumin, glyceraldehyde-3

32 A second glycated beta-Hb isomer that is partially resolved from

33 The values for glycated beta-Hb were found to correlate well with the H

34 ected in extracted ion electropherograms for glycated beta-Hb.

35 n is achieved between alpha-Hb, beta-Hb, and glycated beta-Hb.

36 Measurement of glycated blood proteins, particularly glycated hemoglobi

37 backbone conformation from A to B form when glycated, but does not induce any final transition in DN

38 eanuts and on rAra h 1 that was artificially glycated by incubation with glucose or xylose.

39 Proteins were glycated by incubation with sugars (glucose, methylglyox

40 protein isolates that had been denatured and glycated by thermal treatment.

41 indicated the formation of hydrolysates and glycated compounds with different molecular weight distr

42 on products (MRPs), protein hydrolysates and glycated compounds.

43 To prepare glycated cowpea protein isolate (GCPI) the cowpea flour

44 ity of N-phenacylthiazolium bromide (PTB), a glycated cross-link breaker, in the modulation of period

45 By using ESI-QTOF-MS technique, formation of glycated cytochrome C containing up to 12 glucose moieti

46 terial mutants displayed increased levels of glycated DNA and RNA and exhibited strong mutator phenot

47 e for a rapid and reliable identification of glycated DNA in a reagent-free manner.

48 in contrast to guanine oxidation repair, how glycated DNA is repaired remains undetermined.

49 ws a clear discrimination between native and glycated DNA samples.

50 depleted cells displayed increased levels of glycated DNA, DNA strand breaks, and phosphorylated p53.

51 Hyperglycemia and exposure to advanced glycated end products inactivated MFG-E8, recognizing a

52 lysates showed reduced fluorescence advanced glycated end-products (AGE) and a reduced amount of alph

53 ceptors (TLRs) and the receptor for advanced glycated end-products (RAGE), are upregulated within inf

54 e-associated molecular patterns and advanced glycated endproducts and can trigger cell activation.

55 The glycated Flavourzyme-derived hydrolysates were found to

56 Remarkably, high glucose led to a glycated form of sCD127 that was ineffective as an IL-7

57 Glycated/glycosylated hydrolysates showed superior bioac

58 Amadori rearrangements and the free and mono-glycated guanidine also formed imidazolinone derivatives

59 diabetes remission at 2 years, defined as a glycated haemaglobin A1c (HbA1c) concentration of 6.5% o

60 The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26.

61 /=1500 mg/day), aged 18 years or older, with glycated haemoglobin (HbA1c) 7.0% or greater (>/=53 mmol

62 Anthropometry, glycated haemoglobin (HbA1c) and IgA tissue transglutami

63 more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6.5% (<48 mmol

64 nge glucose and insulin measures, as well as glycated haemoglobin (HbA1c), are used to diagnose and m

65 MATERIAL/METHODS: Glycated haemoglobin (HbA1c), total cholesterol (TCH), h

66 lso associated with improvements in glucose, glycated haemoglobin (HbA1c), weight, waist circumferenc

67 ments of blood lipids, insulin, glucose, and glycated haemoglobin (HbA1c).

68 n delivery (pump or injections) and baseline glycated haemoglobin (HbA1c).

69 years with established type 2 diabetes, mean glycated haemoglobin A1c (HbA1c) concentration of 67 mmo

70 The primary outcome was a change in glycated haemoglobin A1c (HbA1c) from baseline to week 2

71 ts aged 18-80 years with type 2 diabetes and glycated haemoglobin A1c (HbA1c) of 7.0-9.5% on stable m

72 function, lipid profile, glucose tolerance, glycated haemoglobin A1c, salivary cortisol, sitting hei

73 Mean glycated haemoglobin at baseline was 9% (75 mmol/mol) in

74 The primary endpoint was change in mean glycated haemoglobin between baseline and end of the ran

75 At 6 months, mean glycated haemoglobin had decreased by 1.1% (SD 1.2; 12 m

76 , systolic and diastolic blood pressures and glycated haemoglobin in the 1958 British Birth Cohort (1

77 After the run-in period, patients with glycated haemoglobin of 8.0-12.0% (64-108 mmol/mol) were

78 h advanced type 2 diabetes do not meet their glycated haemoglobin targets and randomised controlled s

79 = 32), and were correlated with the level of glycated haemoglobin, glycaemic level, and time of disea

80 least two creatinine, thyrotropin, calcium, glycated haemoglobin, or lithium measurements between Oc

81 It was observed that patients with elevated glycated Hb levels also had higher levels of HSA glycati

82 nctive test lines when challenged with HbA0, glycated HbA0 and HbA2.

83 For type 2 diabetes (glycated hemoglobin <6.5% without medication), sample-si

84 points, P<0.001) and had similar control of glycated hemoglobin (0.3 percentage points, P=0.63).

85 d 10.2 percentage points, respectively), and glycated hemoglobin (10.1 percentage points and 9.4 perc

86 omol/L [IQR, 72-89 micromol/L], P = .61) and glycated hemoglobin (5.9% [IQR, 5.6%-6.1%] vs 5.9% [IQR,

87 Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood

88 sted difference, 1.0 percentage points), and glycated hemoglobin (adjusted difference, 3.4 percentage

89 liflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points

90 Improved glycated hemoglobin (Hb A1c) delays the progression of m

91 oad glucose (PG), 2-h postload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model asse

92 s: colorectal screening rates; diabetes with glycated hemoglobin (HbA1c level) less than 9.0%; diabet

93 om among 321 people with type 2 diabetes and glycated hemoglobin (HbA1c) >58 mmol/mol.

94 ype 2 diabetes were recruited: subjects with glycated hemoglobin (HbA1c) </=7% and subjects with HbA1

95 ; betaPFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA1c) (betaPFOS=0.03%; 95% CI: 0.0

96 ) concentration (-37.0 mg/dL; P < 0.001) and glycated hemoglobin (HbA1c) [-0.97% (-10.6 mmol/mol); P

97 nt increases in hippocampal FC, decreases in glycated hemoglobin (HbA1c) and body fat, and increases

98 A 66-year-old man affected by DME, with glycated hemoglobin (HbA1c) at 6.9%, refractory to laser

99 d the association between food label use and glycated hemoglobin (HbA1c) concentrations.

100 After 12 months, glycated hemoglobin (HbA1c) decreased from 10.3+/-2.4% t

101 has been developed for the determination of glycated hemoglobin (HbA1c) in human blood samples.

102 The level of Glycated hemoglobin (HbA1c) is accordingly examined for

103 Glycated hemoglobin (HbA1c) is one of the most important

104 Glycated hemoglobin (HbA1c) is used to diagnose type 2 d

105 lycemia from birth, resulting in an elevated glycated hemoglobin (HbA1c) level that mimics recommende

106 ex, waist circumference, fat percentage, and glycated hemoglobin (HbA1c) level were recorded chairsid

107 n leakage area at month 36 (P = 0.0137), and glycated hemoglobin (HbA1c) levels at month 36 (P = 0.00

108 ed the association between periodontitis and glycated hemoglobin (HbA1c) levels in individuals withou

109 (20-50 U) and metformin (>/=1500 mg/d) with glycated hemoglobin (HbA1c) levels of 7% to 10% and a bo

110 nfluence of periodontal status on changes of glycated hemoglobin (HbA1c) levels of patients with type

111 Glycated hemoglobin (HbA1c) levels were measured at base

112 Glycated hemoglobin (HbA1c) levels were measured, and pr

113 Glycated proteins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in

114 hievement of good glycemic control, of which glycated hemoglobin (HbA1c) remains the standard clinica

115 in or loss and glycemic control (assessed by glycated hemoglobin (HbA1c) values) in patients from the

116 In multivariable analyses, glycated hemoglobin (HbA1c) was inversely associated wit

117 Higher levels of glycated hemoglobin (HbA1c) were associated with all-cau

118 glucose, C-reactive protein, triglycerides, glycated hemoglobin (HbA1c), and total, low-density lipo

119 The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and ga

120 eplacement of other sugars and its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insu

121 agnostic accuracies of random blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostas

122 glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albu

123 ent of glycated blood proteins, particularly glycated hemoglobin (HbA1c), is an important diagnostic

124 Blood glycated hemoglobin (HbA1c), reflecting the average bloo

125 ed with the diabetes GRS on fasting insulin, glycated hemoglobin (HbA1c), the homeostasis model asses

126 Measurement of glycated hemoglobin (HbA1c), the most widely accepted in

127 led trials (RCTs) that assessed the outcomes glycated hemoglobin (HbA1c), weight, body mass index (BM

128 dy mass index, random blood sugar (RBS), and glycated hemoglobin (HbA1c).

129 trol was assessed according to percentage of glycated hemoglobin (HbA1c).

130 sensor was developed for the recognition of glycated hemoglobin (HbA1c).

131 body mass index (in kg/m(2)): 34.6 +/- 4.3; glycated hemoglobin (HbA1c): 7.3 +/- 1.1%; duration of d

132 n [n = 136; mean +/- SD age: 12.8 +/- 2.6 y; glycated hemoglobin (HbA1c): 8.1% +/- 1.0%; 69.1% using

133 .7%) was associated with a reduction in mean glycated hemoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), f

134 In 2006, 56% of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the

135 Levels of blood glucose/glycated hemoglobin (International Federation of Clinica

136 luble leptin receptor (reduction of 43%) and glycated hemoglobin (reduction of 28%).

137 y; median (IQR), 10 (5-9) y of T2D duration; glycated hemoglobin 7.0% +/- 0.8%; body mass index (in k

138 8 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/=8% during the year) while

139 tensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established

140 cose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [HbA1c]) and survival in all lung tr

141 g plasma glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported phy

142 se [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, an

143 agnosis, sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

144 While adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we fou

145 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.

146 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 2

147 ciation of baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selec

148 The only significant predictor of glycated hemoglobin A1c reduction was waist circumferenc

149 are well-adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mell

150 Tested as continuous variables, glycated hemoglobin A1C, but neither body mass index nor

151 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin we

152 We collected data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, s

153 tions, pain (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, bo

154 y is to investigate the relationship between glycated hemoglobin and circulating levels of interleuki

155 rvention also produced greater reductions in glycated hemoglobin and greater initial improvements in

156 ic red blood cells correlates with levels of glycated hemoglobin and that the mechanical properties o

157 of Germany or Austria), body mass index, and glycated hemoglobin as covariates were used to account f

158 iculated thrombocytosis that correlates with glycated hemoglobin as well as increased plasma S100A8/A

159 e variation, complicates the clinical use of glycated hemoglobin assays for the diagnosis and managem

160 ears after baseline on the basis of either a glycated hemoglobin concentration of at least 6.5% or us

161 moglobin glycation index (HGI), a measure of glycated hemoglobin controlled for blood glucose variati

162 s improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol a

163 Glycated hemoglobin decreased significantly from 8.2 +/-

164 The primary endpoint was change in glycated hemoglobin from baseline.

165 There was no change in glycated hemoglobin in either group: mean, 7.4 (95% CI,

166 h both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providin

167 and with low HDL concentrations and elevated glycated hemoglobin in obese and diabetic patients.CCK r

168 closures do not affect health in general, 2) glycated hemoglobin is insensitive to local foreclosure

169 dard therapy or aggressive therapy (targets: glycated hemoglobin level <6.0%, low-density lipoprotein

170 val [CI], 0.8 to 15.0) for glycemic control (glycated hemoglobin level <7.0%), 9.4 percentage points

171 ed optimal diabetes care (n = 448) (targets: glycated hemoglobin level <7.0%, low-density lipoprotein

172 wer; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0

173 , 1.02; 95% CI, 1.01-1.04) and knowing one's glycated hemoglobin level (odds ratio, 2.00; 95% CI, 1.3

174 , sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.

175 os for death from any cause according to the glycated hemoglobin level for patients with diabetes as

176 Glycated hemoglobin level had poorer test characteristic

177 The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, wi

178 n, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe

179 with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%.

180 was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% o

181 The primary outcome was a glycated hemoglobin level of 6.0% or less with or withou

182 The primary end point was a glycated hemoglobin level of 6.0% or less.

183 diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5%, and an oxygen des

184 ients younger than 55 years of age who had a glycated hemoglobin level of 6.9% or less (</=52 mmol pe

185 ng those younger than 55 years of age with a glycated hemoglobin level of 6.9% or less, as compared w

186 trols were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (</=52 mmol p

187 l study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of

188 , but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not.

189 e patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye e

190 r mean percentage reduction from baseline in glycated hemoglobin level than did patients who received

191 The mean (SD) glycated hemoglobin level was 7.4% (0.5%).

192 At 24 months, the mean glycated hemoglobin level was 7.5+/-1.2% in each group,

193 iabetes was 16.4 years, and the mean (+/-SD) glycated hemoglobin level was 8.4+/-1.7%; 83.9% of the p

194 s was 49+/-8 years, 66% were women, the mean glycated hemoglobin level was 9.2+/-1.5%, and the mean B

195 /-8 years, 68% were women, the mean baseline glycated hemoglobin level was 9.3+/-1.5%, and the mean b

196 etes had poor glycemic control (mean [+/-SD] glycated hemoglobin level, 9.0+/-2.4%), and the rates of

197 points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressu

198 lycemia, and, in adults, resulted in a lower glycated hemoglobin level.

199 1.13; P = .003) for each unit of increase in glycated hemoglobin level.

200 counting for glycemic control in the form of glycated hemoglobin level.

201 primary safety outcome was the change in the glycated hemoglobin level.

202 C-peptide levels, insulin requirements, and glycated hemoglobin level.

203 f 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean differenc

204 The phenomenon of a discrepancy between glycated hemoglobin levels and other indicators of avera

205 The difference in glycated hemoglobin levels between the intensive-therapy

206 ween-group differences in blood pressure and glycated hemoglobin levels during the trial were no long

207 previously been found to reduce glucose and glycated hemoglobin levels in humans.

208 Glycated hemoglobin levels measured by all three primary

209 e fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up.

210 sults show that interindividual variation in glycated hemoglobin levels was evident in diabetes patie

211 Glycated hemoglobin levels were lower with pump therapy

212 Glycated hemoglobin levels were measured using three pri

213 Glycated hemoglobin levels were significantly lower with

214 Secondary outcomes included glycated hemoglobin levels, insulin dose, and body mass

215 Interindividual and ethnic variation in glycated hemoglobin levels, unrelated to blood glucose v

216 al history, antidiabetic medication use, and glycated hemoglobin levels.

217 c blood pressures, and high triglyceride and glycated hemoglobin levels.

218 men, C-reactive protein, lipoprotein(a), and glycated hemoglobin levels.

219 on self-report or fasting serum glucose and glycated hemoglobin levels.

220 progression was also closely related to mean glycated hemoglobin levels.

221 ere among metabolic surgery patients (higher glycated hemoglobin levels; greater percentage of insuli

222 es included blood-pressure, cholesterol, and glycated hemoglobin levels; screening for depression; me

223 Glycated hemoglobin measurements were compared in patien

224 amer-based microfluidic system for automatic glycated hemoglobin measurements.

225 /m(2)) of 39.2 (95% CI: 35.2, 43.3) and mean glycated hemoglobin of 5.3% (95% CI: 4.9%, 5.6%), were s

226 the intention-to-treat population, the mean glycated hemoglobin profile improved in the intervention

227 We used admission glycated hemoglobin to estimate premorbid baseline blood

228 mg per deciliter (2.6 mmol per liter), and a glycated hemoglobin value of 9.0% or lower, according to

229 ological factors assessed, insulin index and glycated hemoglobin values explained 15% and 16% of the

230 The changes in glycated hemoglobin values were similar in the two group

231 n or albuminuria or blood pressure, although glycated hemoglobin was lowered with both diets.

232 rular basement membrane and higher levels of glycated hemoglobin were independent predictors of progr

233 rs are modestly effective in reducing HbA1c (glycated hemoglobin) ( approximately 0.5%) and while the

234 hod for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentration, hemoglobin (Hb) conc

235 holesterol, high C-reactive protein and high glycated hemoglobin).

236 ysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex.

237 syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycerides and uric

238 cholesterol, triglycerides, blood pressure, glycated hemoglobin, and fasting glucose and report the

239 ar reductions in insulin, insulin C-peptide, glycated hemoglobin, and homeostasis model assessment of

240 e intervention group had significantly lower glycated hemoglobin, fasting plasma glucose, plaque inde

241 justment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholestero

242 For every 1% higher glycated hemoglobin, left ventricular mass was higher by

243 ptical coherence tomography, blood pressure, glycated hemoglobin, medications, and changes in such pa

244 positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment le

245 meters controlling for sex, body mass index, glycated hemoglobin, use of oral hypoglycemic drugs, and

246 een the study groups were seen for change in glycated hemoglobin.

247 tion to determine levels of CRP, lipids, and glycated hemoglobin.

248 ng glucose and postload glucose but not with glycated hemoglobin.

249 e foreclosure rate per census-block group on glycated hemoglobin.

250 block group in the prior year and changes in glycated hemoglobin.

251 d by measurement of the cutoff ratio between glycated hemoglobins (HbA1c) and total hemoglobin (Hb),

252 Assessing the types and amounts of glycated hemoglobins present in erythrocytes could provi

253 lar blood glucose levels regardless of which glycated hemoglobins were measured.

254 o five subfractions, four of which contained glycated hemoglobins.

255 ntified peptides in the enriched fraction as glycated, high sensitivity for detection of glycated pep

256 method is not limited to clinical samples of glycated HSA but could be adapted for work with other mo

257 on approach was developed to isolate HSA and glycated HSA from clinical samples, using only 20 muL of

258 in binding by sulfonylurea drugs to in vivo glycated HSA that had been isolated from individual pati

259 ous data that had been obtained for in vitro glycated HSA with similar levels of modification.

260 1c levels did not have the highest levels of glycated HSA.

261 of glycated peptides quantified in in vitro glycated human plasma increased more than 3-fold using t

262 and modified DNA aptamers specifically bound glycated human serum albumin (GHSA), which is an interme

263 The glycated hydrolysates showed reduced fluorescence advanc

264 equencing of modified peptides and assigning glycated Lys residues.

265 trast, only 168 polypeptides contained early glycated lysines, which did not resemble the sites of ad

266 YajL could repair methylglyoxal- and glyoxal-glycated nucleotides and nucleic acids.

267 lpha overexpression significantly suppressed glycated or acetylated low-density lipoprotein-induced c

268 Glycated patatin (PTT) with galactose, galactooligosacch

269 e 2D-LC-HCD-MS/MS platform for comprehensive glycated peptide quantification.

270 lysis of the modified ubiquitin and isomeric glycated peptides (fragments of bovine serum albumin (BS

271 line platform to human plasma identified 376 glycated peptides from 10 mug of protein digests.

272 The number of glycated peptides quantified in in vitro glycated human

273 glycated, high sensitivity for detection of glycated peptides with LOD and LOQ at 1.2 and 2.4 pg, re

274 ility with interday CVs < 20% for 80% of the glycated peptides.

275 ool for identification and quantification of glycated peptides.

276 rabidopsis thaliana The absence of the early glycated precursors of the AGE-modified protein residues

277 oducible online 2D platform is promising for glycated protein analysis of complex clinical samples.

278 n in exposed splenocyte, were evident in the glycated protein treated mice as compared to its native

279 Thereafter, allergic behaviour of this glycated protein was compared with its native form, usin

280 The reduced allergenicity of glycated protein was observed as lesser allergic phenoty

281 Glycated proteins are emerging as good indicators for di

282 Glycated proteins are important biomarkers for age-relat

283 e detection and identification of individual glycated proteins in complex samples using fluorescent b

284 Using this method we identified glycated proteins in human serum, insect hemolymph and m

285 Although the patterns of glycated proteins were only minimally influenced by plan

286 hree aging-specific and eight differentially glycated proteins, four of which were modified in cataly

287 Glycated proteins, such as glycated hemoglobin (HbA1c) o

288 re significantly improved as compared to non-glycated proteins.

289 However, the platform for analysis of glycated proteome has been relatively less well establis

290 -related changes in the Arabidopsis thaliana glycated proteome, including the proteins affected and s

291 The finding of glycated sCD127 in the circulation of patients at onset

292 to 12 glucose moieties were observed, while glycated species containing 6 and 8 glucose moieties wer

293 rameters with the levels of glycosylated and glycated species in a series of small scale experiments,

294 The glycated species of cytochrome C, lysozyme, and beta-cas

295 Cytochrome C had multiple charges in non-glycated state, primarily changing from +13 to +17 posit

296 ystem equipped for ECD, a series of multiply glycated ubiquitin ions was observed.

297 hod of quantitative and qualitative study of glycated ubiquitin was investigated.

298 Ions of the glycated ubiquitin with a defined number of glucose moie

299 ocess (ISP) was hydrolysed with Alcalase and glycated with glucosamine (GlcN) at moderate temperature

300 rmal stability and antioxidative capacity of glycated WP were increased, especially in the presence o